Selected Abstracts for the September 2023 Issue
- PMID: 37278644
- DOI: 10.1097/DCR.0000000000002965
Selected Abstracts for the September 2023 Issue
References
REFERENCE
-
- Yoshino T, Uetake H, Tsuchihara K, et al. Rationale for and design of the PARADIGM study: randomized phase III study of mFOLFOX6 plus bevacizumab or panitumumab in chemotherapy-naïve patients with RAS (KRAS/NRAS) wild-type, metastatic colorectal cancer. Clin Colorectal Cancer. 2017;16:158–163.
LinkOut - more resources
Full Text Sources